174 related articles for article (PubMed ID: 33787580)
21. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas.
Vang R; Gown AM; Farinola M; Barry TS; Wheeler DT; Yemelyanova A; Seidman JD; Judson K; Ronnett BM
Am J Surg Pathol; 2007 May; 31(5):653-63. PubMed ID: 17460447
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical p16 overexpression and Rb loss correlate with high-risk human papillomavirus infection in endocervical adenocarcinomas.
Yasutake N; Yamamoto H; Kuga R; Jiromaru R; Hongo T; Katayama Y; Sonoda K; Yahata H; Kato K; Oda Y
Histopathology; 2024 Jun; 84(7):1178-1191. PubMed ID: 38445509
[TBL] [Abstract][Full Text] [Related]
23. HPV DNA integration site as proof of the origin of ovarian metastasis from endocervical adenocarcinoma: three case reports.
Arfi A; Hequet D; Bataillon G; Tran-Perennou C; Farkhondeh F; Sastre-Garau X; Fourchotte V; Rouzier R; Laas E; Pouget N; Vincent-Salomon A; Jeannot E
BMC Cancer; 2019 Apr; 19(1):375. PubMed ID: 31014281
[TBL] [Abstract][Full Text] [Related]
24. Endocervical adenocarcinoma in situ-from Papanicolaou test to hysterectomy: a series of 74 cases.
Lashmanova N; Braun A; Cheng L; Gattuso P; Yan L
J Am Soc Cytopathol; 2022; 11(1):13-20. PubMed ID: 34509373
[TBL] [Abstract][Full Text] [Related]
25. Unusual endocervical adenocarcinomas: an immunohistochemical analysis with molecular detection of human papillomavirus.
Park KJ; Kiyokawa T; Soslow RA; Lamb CA; Oliva E; Zivanovic O; Juretzka MM; Pirog EC
Am J Surg Pathol; 2011 May; 35(5):633-46. PubMed ID: 21490443
[TBL] [Abstract][Full Text] [Related]
26. ProExC is a novel marker for distinguishing between primary endometrial and endocervical adenocarcinomas.
Esheba GE
J Egypt Natl Canc Inst; 2013 Jun; 25(2):87-93. PubMed ID: 23719407
[TBL] [Abstract][Full Text] [Related]
27. Cervical FISH Testing for Triage and Support of Challenging Diagnoses: A Case Study of 2 Patients.
Hopley R; Gillespie A
Lab Med; 2016 Feb; 47(1):52-6. PubMed ID: 26732782
[TBL] [Abstract][Full Text] [Related]
28. The spectrum of cervical glandular neoplasia and issues in differential diagnosis.
Loureiro J; Oliva E
Arch Pathol Lab Med; 2014 Apr; 138(4):453-83. PubMed ID: 24678677
[TBL] [Abstract][Full Text] [Related]
29. CD10 and calretinin staining of endocervical glandular lesions, endocervical stroma and endometrioid adenocarcinomas of the uterine corpus: CD10 positivity is characteristic of, but not specific for, mesonephric lesions and is not specific for endometrial stroma.
McCluggage WG; Oliva E; Herrington CS; McBride H; Young RH
Histopathology; 2003 Aug; 43(2):144-50. PubMed ID: 12877729
[TBL] [Abstract][Full Text] [Related]
30. Minimal-deviation Endometrioid Adenocarcinoma of the Cervix: A Case Report With Ultrastructural Analysis Demonstrating Abnormal Ciliation of the Tumor Cells.
Gould PR; Stewart CJR; Papadimitriou JM
Int J Gynecol Pathol; 2017 Jan; 36(1):90-94. PubMed ID: 27362904
[TBL] [Abstract][Full Text] [Related]
31. Cytology and curetting diagnosis of endocervical adenocarcinoma.
Bruehl FK; Dyhdalo KS; Hou Y; Clapacs E; Przybycin CG; Reynolds JP
J Am Soc Cytopathol; 2020; 9(6):556-562. PubMed ID: 32624383
[TBL] [Abstract][Full Text] [Related]
32. PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma.
Rabban JT; McAlhany S; Lerwill MF; Grenert JP; Zaloudek CJ
Am J Surg Pathol; 2010 Feb; 34(2):137-46. PubMed ID: 20061933
[TBL] [Abstract][Full Text] [Related]
33. The utility of PAX8 and IMP3 immunohistochemical stains in the differential diagnosis of benign, premalignant, and malignant endocervical glandular lesions.
Danialan R; Assaad M; Burghardt J; Newcomb P; Cartun RW; Mandavilli S
Gynecol Oncol; 2013 Aug; 130(2):383-8. PubMed ID: 23618832
[TBL] [Abstract][Full Text] [Related]
34. Cytomorphologic Features of Gastric-Type Endocervical Adenocarcinoma in Liquid-Based Preparations.
Schwock J; Starova B; Khan ZF; Mirkovic J; Parra-Herran C; Ko HM; Rouzbahman M; Ghorab Z
Acta Cytol; 2021; 65(1):56-66. PubMed ID: 33152741
[TBL] [Abstract][Full Text] [Related]
35. Hormone receptor immunohistochemistry and human papillomavirus in situ hybridization are useful for distinguishing endocervical and endometrial adenocarcinomas.
Staebler A; Sherman ME; Zaino RJ; Ronnett BM
Am J Surg Pathol; 2002 Aug; 26(8):998-1006. PubMed ID: 12170086
[TBL] [Abstract][Full Text] [Related]
36. Recent advances in invasive adenocarcinoma of the cervix.
Stolnicu S; Hoang L; Soslow RA
Virchows Arch; 2019 Nov; 475(5):537-549. PubMed ID: 31209635
[TBL] [Abstract][Full Text] [Related]
37. Immunophenotype analysis using CLDN18, CDH17, and PAX8 for the subcategorization of endocervical adenocarcinomas in situ: gastric-type, intestinal-type, gastrointestinal-type, and Müllerian-type.
Asaka S; Nakajima T; Kugo K; Kashiwagi R; Yazaki N; Miyamoto T; Uehara T; Ota H
Virchows Arch; 2020 Apr; 476(4):499-510. PubMed ID: 31932920
[TBL] [Abstract][Full Text] [Related]
38. Synchronous endometrioid adenocarcinomas in the uterine cervix and corpus.
Obata T; Nakamura M; Mizumoto Y; Matsumoto T; Takakura M; Fujiwara H
J Obstet Gynaecol Res; 2016 Oct; 42(10):1390-1394. PubMed ID: 27354119
[TBL] [Abstract][Full Text] [Related]
39. Endocervical adenocarcinoma and its variants: their morphology and differential diagnosis.
Young RH; Clement PB
Histopathology; 2002 Sep; 41(3):185-207. PubMed ID: 12207781
[TBL] [Abstract][Full Text] [Related]
40. Molecular and pathological basis of HPV-negative cervical adenocarcinoma seen in a global study.
Jenkins D; Molijn A; Kazem S; Pirog EC; Alemany L; de Sanjosé S; Dinjens W; Quint W
Int J Cancer; 2020 Nov; 147(9):2526-2536. PubMed ID: 32474915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
